Status:
COMPLETED
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder
Lead Sponsor:
Gaia AG
Collaborating Sponsors:
Zentrum für Integrative Psychiatrie Kiel
University Hospital, Saarland
Conditions:
Adult Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online int...
Eligibility Criteria
Inclusion
- women, men, non-binary
- age 18-65 years
- diagnosis of ADHD (assessed via DIVA)
- ADHD severity score (cut-off): score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1
- stable treatment (psychotherapy, medication, no treatment, …) for at least 30 days at the time of inclusion
- consent to participation
- sufficient knowledge of the German language
Exclusion
- diagnosis of another severe psychiatric disorder (severe affective disorder, autism spectrum disorder, psychotic disorder, Borderline personality disorder, antisocial personality disorder, substance use disorder, suicidality)
- plans to change treatment (psychotherapy, medication, …) in the upcoming three months after inclusion
Key Trial Info
Start Date :
March 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 25 2024
Estimated Enrollment :
337 Patients enrolled
Trial Details
Trial ID
NCT06221930
Start Date
March 11 2024
End Date
December 25 2024
Last Update
January 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GAIA AG
Hamburg, Germany, 22085